Selinexor (combination therapy)
XPORT-DLBCL-030
Phase 3 small_molecule active
Quick answer
Selinexor (combination therapy) for Relapsed/Refractory Diffuse Large B-cell Lymphoma is a Phase 3 program (small_molecule) at Karyopharm Therapeutics with 1 ClinicalTrials.gov record(s).
Program details
- Company
- Karyopharm Therapeutics
- Indication
- Relapsed/Refractory Diffuse Large B-cell Lymphoma
- Phase
- Phase 3
- Modality
- small_molecule
- Status
- active